People

Michael Smith focuses on securities and shareholder litigation, along with related board investigations. A partner and Co-chair of our Securities and Shareholder Litigation practice, Michael represents corporate clients in a wide range of matters related to corporate governance and fiduciary duties.

Michael represents corporations, officers and directors in a wide variety of shareholder disputes, including securities fraud class actions, shareholder derivative litigation, merger litigation, and audit committee and other board committee investigations. He has appeared in courts throughout the southeastern United States, and in New York, Delaware, California, the District of Columbia, Maryland, Massachusetts, Illinois, Minnesota and Texas.

A frequent speaker and writer on securities litigation topics, Michael has been recognized as a "Litigation Star" by Benchmark Litigation. He has also received recognition from The Best Lawyers in America for as well as from Legal 500 US .

Full Bio

Credentials

A.B., University of Georgia, summa cum laude, Phi Beta Kappa

J.D., Harvard University, cum laude

Georgia

State Bar of Georgia

Atlanta Bar Association

Matters

Defense of Altisource Portfolio Solutions S.A. and directors and officers in 10b-5 securities class action litigation and related shareholder derivative litigation arising out of the company’s 76% share price decline following regulatory settlements forced on the company’s former parent and largest customer.

Defense of TransEnterix, Inc. and its board of directors in 10b-5 securities class action and related shareholder derivative litigation arising out of the FDA’s 2016 rejection of the company’s 501(k) substantial equivalence submission for its robotic surgery system.

Defense of Galectin Therapeutics, Inc. and its directors and officers in 10b-5 securities class action and related shareholder derivative litigation arising out of stock price drop following announcement of results of Phase 1 clinical trial and allegations that Galectin paid a stock promotion firm to place articles touting Galectin and its prospects. Won motions to dismiss both actions in 2015 and 2016. Dismissal of 10b-5 class action affirmed on appeal by the 11th Circuit Court of Appeals.

See more
Icon close

Close

Matters

Defense of Altisource Portfolio Solutions S.A. and directors and officers in 10b-5 securities class action litigation and related shareholder derivative litigation arising out of the company’s 76% share price decline following regulatory settlements forced on the company’s former parent and largest customer.

Defense of TransEnterix, Inc. and its board of directors in 10b-5 securities class action and related shareholder derivative litigation arising out of the FDA’s 2016 rejection of the company’s 501(k) substantial equivalence submission for its robotic surgery system.

Defense of Galectin Therapeutics, Inc. and its directors and officers in 10b-5 securities class action and related shareholder derivative litigation arising out of stock price drop following announcement of results of Phase 1 clinical trial and allegations that Galectin paid a stock promotion firm to place articles touting Galectin and its prospects. Won motions to dismiss both actions in 2015 and 2016. Dismissal of 10b-5 class action affirmed on appeal by the 11th Circuit Court of Appeals.

Defense of Popeyes Louisiana Kitchen, Inc. and its board of directors in a federal securities class action in Minnesota challenging the company’s 2016 merger with Restaurant Brands International, Inc.

Defense of EndoChoice Holdings and its board of directors in securities class action litigation under the Securities Act of 1933 challenging the company’s 2015 initial public offering.

Defense of World Acceptance Corporation in federal securities class action and related shareholder derivative litigation arising out of a regulatory investigation by the Consumer Financial Protection Bureau.

Defense of Aeterna Zentaris, Inc. and its directors and officers in 10b-5 securities class action litigation arising out of stock price drop following announcement of the FDA’s rejection of the company’s NDA for approval of its Macrilen drug for testing of Adult Growth Hormone Deficiency.

Defense of Carmike, Inc. in federal securities class action litigation challenging the company’s proxy disclosures in connection with the 2016 merger of Carmike with AMC Theatres.

Matters

Defense of Altisource Portfolio Solutions S.A. and directors and officers in 10b-5 securities class action litigation and related shareholder derivative litigation arising out of the company’s 76% share price decline following regulatory settlements forced on the company’s former parent and largest customer.

Defense of TransEnterix, Inc. and its board of directors in 10b-5 securities class action and related shareholder derivative litigation arising out of the FDA’s 2016 rejection of the company’s 501(k) substantial equivalence submission for its robotic surgery system.

Defense of Galectin Therapeutics, Inc. and its directors and officers in 10b-5 securities class action and related shareholder derivative litigation arising out of stock price drop following announcement of results of Phase 1 clinical trial and allegations that Galectin paid a stock promotion firm to place articles touting Galectin and its prospects. Won motions to dismiss both actions in 2015 and 2016. Dismissal of 10b-5 class action affirmed on appeal by the 11th Circuit Court of Appeals.

See more
Icon close

Close

Matters

Defense of Altisource Portfolio Solutions S.A. and directors and officers in 10b-5 securities class action litigation and related shareholder derivative litigation arising out of the company’s 76% share price decline following regulatory settlements forced on the company’s former parent and largest customer.

Defense of TransEnterix, Inc. and its board of directors in 10b-5 securities class action and related shareholder derivative litigation arising out of the FDA’s 2016 rejection of the company’s 501(k) substantial equivalence submission for its robotic surgery system.

Defense of Galectin Therapeutics, Inc. and its directors and officers in 10b-5 securities class action and related shareholder derivative litigation arising out of stock price drop following announcement of results of Phase 1 clinical trial and allegations that Galectin paid a stock promotion firm to place articles touting Galectin and its prospects. Won motions to dismiss both actions in 2015 and 2016. Dismissal of 10b-5 class action affirmed on appeal by the 11th Circuit Court of Appeals.

Defense of Popeyes Louisiana Kitchen, Inc. and its board of directors in a federal securities class action in Minnesota challenging the company’s 2016 merger with Restaurant Brands International, Inc.

Defense of EndoChoice Holdings and its board of directors in securities class action litigation under the Securities Act of 1933 challenging the company’s 2015 initial public offering.

Defense of World Acceptance Corporation in federal securities class action and related shareholder derivative litigation arising out of a regulatory investigation by the Consumer Financial Protection Bureau.

Defense of Aeterna Zentaris, Inc. and its directors and officers in 10b-5 securities class action litigation arising out of stock price drop following announcement of the FDA’s rejection of the company’s NDA for approval of its Macrilen drug for testing of Adult Growth Hormone Deficiency.

Defense of Carmike, Inc. in federal securities class action litigation challenging the company’s proxy disclosures in connection with the 2016 merger of Carmike with AMC Theatres.

Credentials

A.B., University of Georgia, summa cum laude, Phi Beta Kappa

J.D., Harvard University, cum laude

Georgia

State Bar of Georgia

Atlanta Bar Association